PDA (Patent Ductus Arteriosus) Ligation — Cost, Top Hospitals & Success Rates | MyMedicPlus

The ductus arteriosus is a normal fetal blood vessel that connects the main pulmonary artery to the descending aorta, allowing blood to bypass the uninflated lungs during intrauterine life. Within the first 24–72 hours after birth, rising oxygen levels and falling prostaglandin concentrations trigger functional closure, followed by permanent anatomical closure (ligamentum arteriosum) over the next 2–3 weeks.

In patent ductus arteriosus (PDA), this vessel fails to close and remains open (patent), creating an abnormal left-to-right shunt — that is, oxygenated blood from the high-pressure aorta flows back into the lower-pressure pulmonary circulation. The haemodynamic consequences depend on the size of the PDA: small PDAs may be clinically silent, while large ones cause pulmonary overcirculation, heart failure, and, over decades, irreversible pulmonary hypertension (Eisenmenger syndrome).

PDA is one of the most common congenital heart defects, accounting for approximately 5–10% of all congenital heart disease. It is particularly prevalent in premature infants — occurring in up to 70% of infants born before 28 weeks gestation — because prostaglandin sensitivity is higher at earlier gestational ages.

PDA closure can be achieved by pharmacological therapy (indomethacin or ibuprofen in premature neonates), surgical ligation, or transcatheter device occlusion. Surgical ligation was the standard for over 50 years; transcatheter closure is now the preferred approach for haemodynamically stable patients weighing more than approximately 3–5 kg.

PDA ligation or device closure addresses the patent ductus arteriosus itself, but its haemodynamic effects drive the clinical indications:

• Symptomatic PDA in premature neonates: Respiratory distress, ventilator dependency, poor feeding, necrotising enterocolitis, and intraventricular haemorrhage exacerbated by left-to-right shunting and pulmonary oedema. Surgical ligation is indicated after indomethacin/ibuprofen fails or is contraindicated.
• Moderate-to-large PDA in term infants and children: Heart failure symptoms, pulmonary hypertension, or significant left ventricular volume overload (left atrial and ventricular dilatation on echocardiography) indicating transcatheter or surgical closure.
• Silent PDA with endarteritis risk: Even small PDAs carry a lifetime risk of infective endarteritis (approximately 0.45% per year). Some guidelines recommend closure of all haemodynamically significant PDAs and selected small PDAs in young patients to eliminate this risk.
• Unrepaired PDA in adults: Older patients with previously undetected PDA presenting with dyspnoea, pulmonary hypertension, or incidental echocardiographic findings. Transcatheter closure is standard in adults if pulmonary vascular resistance is not prohibitively elevated.

Eligibility for PDA closure and selection of technique depend on patient size, age, PDA morphology, and haemodynamic status:

Transcatheter Device Closure (Preferred in ≥3–5 kg Patients)

• Weight ≥3 kg (some devices approved for ≥2 kg with operator experience)
• Echocardiographically confirmed significant left-to-right shunt with left atrial or ventricular enlargement
• Favourable PDA morphology (conical or window-type) assessed by echocardiography and angiography
• Pulmonary vascular resistance <8 Wood units (reversible or predominantly reactive pulmonary hypertension)

Surgical Ligation

• Very low birth weight premature neonates (<3 kg) where transcatheter access is technically not feasible
• Failed or contraindicated indomethacin/ibuprofen therapy in symptomatic neonates
• PDA morphology unsuitable for catheter-based devices (e.g., aneurysmal PDA, very short or window-type defects in neonates)
• Concurrent cardiac lesions requiring open surgical repair

Ineligibility: Patients with Eisenmenger syndrome (fixed pulmonary vascular disease with pulmonary pressure exceeding systemic — causing reversal to right-to-left shunt) are not candidates for closure and require pulmonary vasodilator therapy instead.

Three main approaches exist for PDA closure; the cardiologist or cardiac surgeon selects the most appropriate based on patient profile:

Pharmacological Closure (Premature Neonates Only)

Indomethacin (a COX inhibitor) or ibuprofen is administered intravenously to inhibit prostaglandin synthesis and promote ductal constriction. Success rates of 70–80% in premature neonates born before 32 weeks. Contraindicated with renal impairment, thrombocytopaenia, or necrotising enterocolitis. Not effective in term infants or older patients.

Transcatheter Device Occlusion

Performed in the cardiac catheterisation laboratory under sedation or light general anaesthesia. A catheter is introduced through the femoral vein or artery and advanced to the PDA under fluoroscopic guidance. A nitinol (nickel-titanium alloy) device — most commonly the Amplatzer Duct Occluder, PiccoloTM Occluder (for neonates), or coils for small PDAs — is deployed to mechanically block the ductus. Complete closure rates exceed 99% at 12 months. Device embolisation (<1%) and left pulmonary artery stenosis (<2%) are rare but recognized complications.

Surgical Ligation

Performed under general anaesthesia through a small left posterolateral thoracotomy (chest incision) at the level of the third or fourth intercostal space without the need for cardiopulmonary bypass. The surgeon identifies and doubly ligates or clips the ductus arteriosus. The chest is closed primarily. In premature neonates, the procedure is often performed at the bedside in the neonatal intensive care unit (NICU) under local anaesthesia with sedation to avoid transport risks. Video-assisted thoracoscopic surgery (VATS) is used in selected centres for minimally invasive ligation.

VATS (Video-Assisted Thoracoscopic) Ligation

Three small keyhole incisions replace the open thoracotomy incision. Three or four ports allow a camera and instruments to clip the PDA under thoracoscopic vision. Used in infants and children over approximately 5 kg. Faster recovery, less post-operative pain, and no rib spreading compared to open surgery.

Timely PDA closure — whether surgical or catheter-based — restores normal cardiac and pulmonary physiology with lasting benefits:

• Elimination of the left-to-right shunt: Pulmonary blood flow normalises immediately, reducing pulmonary oedema, improving lung compliance, and facilitating weaning from mechanical ventilation in premature infants.
• Prevention of Eisenmenger syndrome: Closing the PDA before irreversible pulmonary vascular remodelling occurs (typically before age 2–3 years) prevents the development of fixed pulmonary hypertension and its associated mortality.
• Heart failure resolution: Left ventricular volume overload from the shunt reverses after closure; LV dimensions normalise within weeks to months.
• Infective endarteritis prevention: Turbulent jet flow through the PDA creates an endarteritis nidus; closure eliminates this risk permanently.
• Long-term cardiac protection: Patients with closed PDA have normal life expectancy if closure occurs before pulmonary hypertension is established.
• Low surgical morbidity: Surgical PDA ligation in experienced centres carries <0.5% mortality in otherwise stable patients. Transcatheter closure is a day-case procedure with 99%+ procedural success.

Both surgical and catheter-based PDA closure are highly safe procedures, but specific risks apply to each approach:

Surgical Ligation Risks

• Left recurrent laryngeal nerve injury: The nerve loops around the ductus arteriosus and is at risk of traction injury during dissection. Transient hoarseness or left vocal cord palsy occurs in 0.5–3% of cases. Permanent injury is rare.
• Inadvertent aorta or pulmonary artery ligation: An extremely rare but serious error where the ductus is not properly identified. Risk is minimised by surgeon experience and intraoperative echocardiography.
• Chylothorax: Injury to the thoracic duct causes lymph accumulation in the pleural space, requiring dietary modification (medium-chain triglyceride formula) or surgical ligation in 1–2% of cases.
• Pneumothorax and haemothorax: Pleural complications at the surgical site requiring drainage.
• Anaesthesia risks in premature neonates: Including hypothermia, apnoea, and haemodynamic instability — managed by experienced neonatal anaesthetists.

Transcatheter Closure Risks

• Device embolisation (<1%): The device migrates from the PDA into the heart or pulmonary artery. Requires surgical or catheter retrieval.
• Left pulmonary artery protrusion (<2%): The device encroaches on the left pulmonary artery ostium, causing partial obstruction. Usually resolves over time but may require repositioning.
• Haematoma at femoral access site: Minor bruising or haematoma in 1–3% of cases.
• Residual shunt: Small residual leaks at 24 hours close spontaneously in most cases. Significant residual shunting (<1%) may require re-intervention.

Recovery timelines differ substantially between neonatal surgical ligation and elective transcatheter closure in older patients.

After Neonatal Surgical Ligation

Premature neonates remain in the NICU post-operatively and are monitored for respiratory improvement, haemodynamic stability, and renal function. Ventilator settings are progressively reduced as pulmonary oedema resolves, typically over 24–72 hours. The chest wound (2–3 cm incision) heals within 1–2 weeks. Full NICU discharge timelines are driven by the infant's overall prematurity and co-morbidities rather than the PDA procedure itself.

After Transcatheter Device Closure (Older Infants, Children, Adults)

Most patients are discharged home the same day or the following morning. Femoral access site requires pressure dressing for 6 hours and activity restriction for 48 hours. A follow-up transthoracic echocardiogram is performed at 24 hours (pre-discharge), 1 month, 6 months, and 12 months to confirm device position and complete closure.

Activity and Medications

Anti-platelet therapy (aspirin 3–5 mg/kg/day) is prescribed for 6 months post-device closure to prevent thrombus formation on the occluder while endothelium grows over the device surface. Contact sports and strenuous activity are restricted for 3–6 months. Infective endocarditis antibiotic prophylaxis is recommended for 6 months after device placement.

Long-Term Outcome

After complete PDA closure in the absence of fixed pulmonary hypertension, cardiac function normalises and patients require no further cardiac restriction or medication. Life expectancy is normal. Annual cardiology review is recommended for the first 5 years; thereafter, patients may be discharged from cardiology follow-up if fully asymptomatic with normal echocardiography.

The cost of PDA closure varies significantly between neonatal surgical ligation (typically during NICU care) and elective transcatheter closure in older patients. Key variables include:

• Patient age and complexity: Premature neonate ligation costs are often absorbed within the overall NICU admission cost. Elective catheter-based closure in a healthy child or adult is an outpatient-equivalent procedure with much lower total cost.
• Device cost: Amplatzer Duct Occluder and similar nitinol occluder devices carry significant per-unit costs (USD 1,500–3,000 for the device alone). Coil closure for small PDAs is less expensive.
• Catheterisation laboratory fees: Include fluoroscopy suite, team, and contrast materials.
• Surgical approach: VATS ligation in an infant in a high-resource centre includes paediatric cardiac surgical and anaesthesia fees, thoracic instrumentation, and PICU admission.
• Country of treatment: Medical tourism for PDA closure is growing. Experienced paediatric cardiac centres in India (e.g., Narayana Health, Apollo Hospitals), Thailand, and Turkey provide transcatheter and surgical PDA closure at 50–70% below US or UK costs, with outcomes equivalent to top Western centres. JCI-accredited facilities are recommended.

In appropriately selected patients, non-surgical and less invasive alternatives to open surgical ligation exist:

• Pharmacological therapy (indomethacin/ibuprofen): First-line in premature neonates under 32 weeks gestational age. Achieves ductal closure in approximately 70–80% without surgical risk. Not effective in term infants or children.
• Transcatheter device closure: Now the preferred method for virtually all patients above 3–5 kg. Same-day discharge, no surgical incision, >99% success rate. Supersedes surgery for most elective cases.
• Conservative (watchful waiting): For haemodynamically insignificant (small, restrictive) PDAs in asymptomatic older children and adults with no left-heart enlargement. Many of these defects cause no harm and the risk of intervention may outweigh the benefit of closure. Serial echocardiographic monitoring is appropriate.
• VATS (thoracoscopic) ligation: For patients where catheter closure is not feasible (very small weight, unfavourable anatomy) and open thoracotomy is avoidable. Less invasive than conventional surgery.
• Hybrid procedure: In very premature, haemodynamically unstable neonates unsuitable for either pharmacotherapy or catheter closure, a hybrid approach using intraoperative device deployment via direct ductal puncture has been described in specialised centres.